Johnson & Johnson

J&J recalls 47mn packages of drugs Sun, 16/01/2011 - 16:28 by Neka Sehgal In what can be termed as yet another blow to Johnson & Johnson, which has been struggling with manufacturing and quality control troubles for well over a year, the company is recalling almost 47 million units of over-the-counter medicines due to inadequate cleaning procedures. Comments Read more	Rolaids recalled over 'foreign materials' Fri, 10/12/2010 - 07:13 by harsheeb NewBrunwick -- Johnson & Johnson is recalling about 13 million packages of Rolaids Softchews the company says may contain metal and wood particles. In a statement, the company said the "foreign materials" were "potentially introduced into the product during the manufacturing process by a third party manufacturer" and that "the risk of serious adverse health consequences is remote," WebMD.com reported Thursday. The action is the latest in a series of recalls affecting J&J's McNeil division this year. The company recalled various lots of Mylanta, Tylenol, Children's Benadryl, Junior Strength Motrin and Pepcid products. Comments Read more	Quality issues plague McNeil drug plant Sat, 27/11/2010 - 22:54 by harsheeb Washington -- Federal inspectors said a Johnson & Johnson drug making plant in Puerto Rico had yet to meet quality control standards spelled out by letter in January. The plant operated by McNeil Consumer Healthcare, a unit of the Johnson & Johnson conglomerate, recalled millions of bottles of over the counter drugs, including Tylenol and Motrin, in January, The New York Times reported Saturday. Johnson & Johnson also recalled 136 million bottles of liquid children's Tylenol and other medicines in April, although these were made in Pennsylvania, the Times said. Comments Read more
J&J recalls children’s Benadryl, Motrin, Rolaids Wed, 24/11/2010 - 13:35 by Neha Gupta In yet another recall, Johnson & Johnson subsidiary McNeil Consumer Healthcare has called back almost 5 million packages of two children’s medicines. Comments Read more	7 Pharma Stocks Near 52-Week Highs Sat, 30/10/2010 - 22:33 by Anand Chokkavelu I love bargain stocks, especially when they're hitting 52-week lows. Still, it can be instructive to also look at stocks that are riding high. Comments Read more	5 Companies You Can Buy Today Tue, 26/10/2010 - 12:31 by Morgan Housel There are many ways to value a company. Price to earnings. Price to cash flow. Liquidation value. Price per eyeballs on website. Price to a number I completely made up (this one never gets old). Price to CEO's ego divided by lobbying activity as a percentage of revenue (this one doesn't get used enough). Comments Read more
Watch a 40% Decline Disappear Wed, 20/10/2010 - 11:22 by Brian Orelli The greatest thing going for Johnson & Johnson (NYSE: JNJ) is its diversity in product offerings. Comments Read more	FDA pulls up mouthwash manufacturers over marketing claims Wed, 29/09/2010 - 14:58 by Jamie Anderson The Food and Drug Administration (FDA) continued to crack the whip on marketers who make unproven claims in their advertising campaigns when it issued warning letters to three sellers of mouth-rinse products. Comments Read more	Bond Bubbles! Bond Bubbles! Sat, 04/09/2010 - 11:05 by Morgan Housel Bond bubble talk is rife these days. Maybe it's because we've become, as one economist put it, "armageddon hypochondriacs." Recent experience leads us to believe that markets are always on the brink of insanity and meltdown. Comments Read more
Bond Investors Got a Fever -- and the Only Prescription Is More Yield Tue, 24/08/2010 - 12:09 by Jacob Roche Johnson & Johnson (NYSE: JNJ) recently broke a new record -- but it wasn't for the strongest Tylenol in history. J&J has now posted the lowest yields ever on a corporate 10-year and 30-year bond -- 2.95% and 4.50% respectively. For comparison's sake, that's 21 and 56 basis points more than comparable Treasury bonds. Comments Read more	It's Hard to Get Excited About 92% Revenue Growth Sat, 31/07/2010 - 12:34 by Brian Orelli Merck (NYSE: MRK) beat analysts' earnings expectations in the second quarter, but it's hard to get excited about decreasing costs and lower taxes especially considering the risks the drugmaker faces. Comments Read more	7 High-Quality Stocks for 7 Lean Years Thu, 29/07/2010 - 11:28 by Matthew Argersinger For us hope-to-be-elite investors, it pays to check in with what the already-elite investors are doing and saying. In fact, we all could have made a lot of money over the past decade had we listened to Jeremy Grantham, the chairman of asset manager GMO. Comments Read more